| Tamoxifen-treated patients (cohort 1) | Untreated patients | ||||||
---|---|---|---|---|---|---|---|---|
 | 0.0 to 2.5 yearsa | 5.0 to 10.0 yearsa,c | 0.0 to 2.5 yearsb | 5.0 to 10.0 yearsb,c | ||||
Variable | Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | Hazard ratio(95% CI) | P | Hazard ratio(95% CI) | P |
Age, analyzed as a continuous variable | 1.04 (0.99, 1.08) | 0.071 | 1.02 (0.98, 1.07) | 0.279 | 1.01 (0.98, 1.05) | 0.357 | 1.04 (0.99, 1.08) | 0.063 |
Tumor (T) stage, T2/3 vs T1 | 2.29 (0.87, 6.08) | 0.094 | 2.90 (1.22, 6.91) | 0.016 | 1.88 (0.74, 4.80) | 0.183 | 1.22 (0.48, 3.12) | 0.677 |
Nodal status, positive vs negative | 2.92 (1.23, 6.88) | 0.014 | 2.46 (1.15, 5.23) | 0.021 | - | - | Â | Â |
Grade 2 or 3 vs 1 | 1.51 (0.33, 6.78) | 0.592 | 0.72 (0.31, 1.69) | 0.451 | 2.13 (0.28, 16.4) | 0.467 | 1.07 (0.29, 3.95) | 0.923 |
HER2-positive vs -negative | 1.42 (0.33, 6.78) | 0.528 | 1.63 (0.31, 1.69) | 0.667 | 4.24 (1.36, 13.1) | 0.013 | 2.89 (0.57, 14.6) | 0.198 |
MKS/ERS (ref lowMKS/highERS) | Â | Â | Â | Â | Â | Â | Â | Â |
   lowMKS/lowERS | 2.65 (0.48, 14.7) | 0.269 | 3.53 (1.21, 10.2) | 0.021 | 1.67 (0.10, 27.1) | 0.717 | 0.46 (0.09, 2.33) | 0.349 |
   highMKS/highERS | 1.28 (0.18, 9.23) | 0.807 | 4.59 (1.56, 13.5) | 0.006 | 11.6 (1.41, 95.2) | 0.023 | 1.82 (0.53, 6.27) | 0.343 |
   highMKS/lowERS | 10.0 (2.21, 45.5) | 0.003 | 0.95 (0.20, 4.70) | 0.947 | 9.56 (1.17, 77.8) | 0.035 | 1.51 (0.44, 5.14) | 0.508 |